Qiagen N.V. (QGEN)

NYSE: QGEN · Real-Time Price · USD
46.92
+0.42 (0.90%)
At close: Sep 2, 2025, 4:00 PM
46.92
0.00 (0.00%)
After-hours: Sep 2, 2025, 7:00 PM EDT
0.90%
Market Cap10.16B
Revenue (ttm)2.04B
Net Income (ttm)373.39M
Shares Out 216.56M
EPS (ttm)1.69
PE Ratio27.71
Forward PE19.51
Dividend$1.51 (3.25%)
Ex-Dividend DateJul 2, 2025
Volume2,411,083
Open47.35
Previous Close46.50
Day's Range46.62 - 47.38
52-Week Range37.63 - 51.88
Beta0.64
AnalystsBuy
Price Target51.01 (+8.72%)
Earnings DateAug 5, 2025

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]

Sector Healthcare
IPO Date Jun 28, 1996
Employees 5,967
Stock Exchange NYSE
Ticker Symbol QGEN
Full Company Profile

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.01, which is an increase of 8.72% from the latest price.

Price Target
$51.01
(8.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAsta...

23 hours ago - Business Wire

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

5 days ago - Business Wire

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

5 days ago - Business Wire

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

5 days ago - Business Wire

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low...

12 days ago - Seeking Alpha

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

Qiagen N.V. (NYSE:QGEN) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers -...

27 days ago - Seeking Alpha

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the fu...

4 weeks ago - Business Wire

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enri...

6 weeks ago - Business Wire

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q2 2025 and hold webcast.

2 months ago - Business Wire

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman ...

2 months ago - Business Wire

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.

2 months ago - Market Watch

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assa...

2 months ago - Business Wire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...

Other symbols: INCY
2 months ago - Business Wire

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Sta...

3 months ago - Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partner...

3 months ago - Business Wire

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic,...

3 months ago - PRNewsWire

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...

3 months ago - Business Wire

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential

QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panel...

3 months ago - Seeking Alpha

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox,...

4 months ago - Business Wire

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Berna...

4 months ago - Seeking Alpha

QIAGEN announces plans for transition in leadership of Supervisory Board

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to ...

4 months ago - Business Wire

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and ...

4 months ago - Business Wire

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual c...

4 months ago - Business Wire

Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value

Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.

4 months ago - CNBC

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPC...

4 months ago - Business Wire